The novel coronavirus disease (COVID-19) pandemic remains a global public health crisis,
presenting a broad range of challenges. To help address some of the main problems, the …

Infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and
vaccinations targeting the spike protein (S) offer protective immunity against coronavirus …

The diversity of vaccination modalities and infection history are both variables that have an
impact on the immune memory of individuals vaccinated against SARS-CoV-2. To gain more …

We describe the molecular-level composition of polyclonal immunoglobulin G (IgG) anti-
spike antibodies from ancestral severe acute respiratory syndrome coronavirus 2 (SARS …

The 2003 severe acute respiratory syndrome coronavirus (SARS-CoV-1) causes more
severe disease than SARS-CoV-2, which is responsible for COVID-19. However, our …

Background and Methods The SARS-CoV-2 (severe acute respiratory syndrome
coronavirus 2) Omicron (B. 1.1. 529) variant is the antigenically most distinct variant to date …

We assessed a cohort of people living with human immunodeficiency virus (PLWH)(n= 110)
and HIV negative controls (n= 64) after 1, 2 or 3 SARS-CoV-2 vaccine doses. At all …

Background We estimate effectiveness of 3 versus 2 vaccine doses against SARS-CoV-2 B.
1.1. 529 Omicron in a mostly infection-naiive but highly vaccinated Australian population …

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) enters host cells by first
engaging its cellular receptor angiotensin converting enzyme 2 (ACE2) to induce …

Background The immune response to adenoviral COVID-19 vaccines is affected by the
interval between doses. The optimal interval is unknown. Aim We aim to explore in-silico the …